An Ancient Diary Reveals How 3 Horrifying Summers May Have Altered the Path of an Entire Nation
An abnormally cold period known as the Little Ice Age significantly cooled down most of Europe during the late 16th through early 19th centuries, but historical documents reveal it had the opposite effect on some regions.
Transylvania experienced some cold flashes, but mostly suffered from punishingly hot summers that resulted in famine and a boom in the rodent population that spread the Bubonic Plague.
While the Little Ice Age was not caused by human activity, researchers think that historical records like this are valuable in helping us determine how to prepare for natural disasters and prevent anthropogenic climate change in the future.
The yellowed and sometimes barely legible pages of 16th-century texts speak of disaster after disaster—from the Black Death to locust invasions to a period of intense climate change that ravaged Transylvania.
The Little Ice Age, as it's now known, was a period during which the expansion of mountain glaciers had a severe impact on the European climate. From the 16th to the mid-19th century, the unusual weather patterns caused most of Europe to experience what seemed like an everlasting winter. But, oddly enough—as a team of researchers found out when they looked through pages of chronicles and diaries from the period—Transylvania instead suffered from strangely hot weather that led to famine and a Bubonic Plague epidemic.
'The analysis of the periods in which the testimonies were recorded indicates that the great majority of the analyzed century is characterized by relatively warm weather, with hot summers and hot years, particularly cold winters and cold years, being mentioned very rarely,' the research team said in a study recently published in Frontiers in Climate.
People have a tendency to record extremes in weather. For instance, there was once a summer that saw hail the size of goose eggs, and it was so warm one autumn that strawberries were still growing in October. Years for which few weather records (if any) can be found probably mean that those years saw a brief respite in extreme weather.
The Little Ice Age did bring a few cold flashes to the Transylvania region. Some writings from 1510 record a winter so harsh that hay for livestock dried up and led to a string of thefts, while others from 1550 recall a winter that dragged on until May. But alas, much more common were the heat waves, which written records attest continued for several consecutive years.
There were three significant hot periods in Transylvania at the time, but the worst undoubtedly started in 1527, and is thought to be the longest period of hot weather during the entire 16th century. There were eleven years of scorching, dry summers that often led to locust invasions—sometimes, it even became unnaturally dark during the day because the entire sky was thick with locusts. Grain crops were destroyed by the insects and led to famine. It only grew worse from there.
'The poor harvests of the rainy years and the atypical weather from the fall of 1553 and the winter towards 1554, sunny as if it were spring, caused the malnutrition that facilitated the terrible plague epidemic of 1553–1554, especially in the south of Transylvania,' one written record states.
While mortality from starvation increased during the famine, nothing took so many lives as the Bubonic Plague. Warmer climates can cause rodent populations to explode, and this is most likely how the Plague—which was carried largely by fleas on rodents such as rats—spread through Transylvania. Also known as the Black Death, the Bubonic Plague had at least a 60-80% mortality rate, and easily wiped out much of a population already weak from famine. Some tried fleeing to the mountains to escape it, but only ended up starving to death.
While many people of the time believed that storms, infestations, and disease were some form of divine retribution, scientists now know that disruptions in climate have much more tangible causes. The Little Ice Age was not the result of human activity, but the researchers who read through all these accounts think that such documents could teach us more about those causes and possibly help us prevent anthropogenic climate change in the future.
'By corroborating historical sources with modern proxy data, not only a deeper understanding of past climate variability,' the team said in the study, 'but also obtaining relevant information for managing current and future climate variability.'
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER
The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. The trial will be the first to study the effects of psilocybin in the treatment of prolonged grief disorder. "In an aging society where people may outlive their family members by decades, it is crucial to develop treatment options for those with prolonged grief disorder," said Dr. Rebecca Böhme, Associate Professor at the Linkoping Center for Social and Affective Neuroscience. "This trial will assess whether psilocybin can improve adaptation to the loss experience. We are grateful to Filament Health for facilitating this research." People with prolonged grief disorder are at a 20 percent increased mortality risk. Previous psychological research suggests that the loss of a close person affects self-identity, an aspect of the higher cognitive self. Psilocybin is suggested to cause a transient shift from reliance on prior experiences towards current sensations. The clinical trial at Linkoping University will utilize this shift combined with a self-touch intervention to support re-learning about the bodily self in a trial population of 120 individuals. "We're pleased to provide PEX010 to Linkoping University for this much-needed area of research," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "This will be the ninth European clinical trial to study our drug candidate, positioning Filament as the region's leading supplier of GMP psilocybin." The trial at Linkoping University is expected to begin dosing in Q3 2025. PEX010 is authorized for investigation in 52 clinical trials worldwide for 14 mental health indications. ABOUT FILAMENT HEALTH (OTC:FLHLF)Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATIONCertain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws. SOURCE Filament Health Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
24 minutes ago
- Business Wire
Sofinnova Partners Collaborates With NVIDIA to Accelerate European Life Sciences Startups
PARIS--(BUSINESS WIRE)-- Sofinnova Partners ('Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a collaboration with NVIDIA to support its portfolio of life sciences startups. The collaboration delivers significant Graphics Processing Unit (GPU) credits to select Sofinnova portfolio companies, effectively giving access to the same computational firepower used by tech titans in Silicon Valley. Amidst increasing demand for computational resources driven by AI, Sofinnova's portfolio companies will be able to access NVIDIA Blackwell and other NVIDIA architecture GPUs via NVIDIA DGX Cloud Lepton, an AI platform and marketplace connecting developers to global AI infrastructure. BioCorteX, Bioptimus, Cure51 and Latent Labs —four of Europe's most promising digital medicine startups—will gain access to computing resources through DGX Cloud Lepton, enabling them to process biological data sets and run computational models that would have taken months, completing them in days. Cure51, a pioneer in decoding the biology of exceptional cancer survivors, tested NVIDIA Parabricks, a GPU-accelerated genomics toolkit, and achieved up to 17x faster processing with NVIDIA H100 GPUs and more than 2x cost savings with NVIDIA L4 GPUs compared to their CPU baseline—dramatically accelerating their ability to analyze complex genomic data and scale their survivor-based insights. "This collaboration supercharges computation for life sciences innovation," said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. "The convergence of biology, AI, computation, and data isn't just our investment thesis—it's the defining battleground of the next decade. From our Digital Medicine strategy to our own proprietary AI platform we recognize the transformative potential of AI across our entire domain. By securing access to NVIDIA's infrastructure, we're not just funding companies; we're empowering them with the computational backbone needed to outperform incumbents and redefine what's possible in drug discovery, precision medicine, and scalable solutions that address both human health and sustainability." Learn more about NVIDIA DGX Cloud Lepton and view the official NVIDIA announcement. ### About Sofinnova Partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit:


Forbes
36 minutes ago
- Forbes
Nvidia Announces Massive New Initiatives in Pharma And Clinical Research
Nvidia has quickly become a leader in the AI ecosystem. Founder and CEO of Nvidia, Jensen Huang, announced today in his GTC Paris keynote that the company has inked two new large partnerships to advance the company's work in healthcare and life-sciences. The first is with European based global pharmaceutical giant, Novo Nordisk, to advance drug discovery and development efforts by leveraging an existing partnership with the Danish Centre for AI Innovation's (DCAI) Gefion AI supercomputer. Novo Nordisk will utilize Gefion and a variety of Nvidia platforms such as BioNeMo, Nim, and Omniverse to build and develop customized AI models, foster agentic AI workflows and even create simulation and digital twin environments to advance physical AI applications. The primary goal will be to use these tools to better understand potential drug candidates and structures in order to build molecular models that can further the drug discovery and development pipeline. Rory Kelleher, senior director of business development for life sciences at Nvidia, explains that drug discovery can claim massive benefits from generative AI, especially in the R&D space. Mishal Patel, senior vice president of AI and digital innovation at Novo Nordisk, comments that the combination of Gefion and Nvidia's computing platforms is an unprecedented approach and will enable the building of custom models that can truly empower better efficiency and efficacy. More generally, Gefion is a computational behemoth and has been used by numerous enterprises to advance their computing capabilities; for example, Danish startup Teton has been working with Nvidia and Gefion to build out an AI care companion for clinical settings. The second partnership that Nvidia announced today is with IQVIA to advance the use of AI agents in the clinical research and commercialization spaces. The companies will collaborate to launch multiple AI powered agents to accelerate pharmaceutical development workflows for biotech and medical device customers globally. Importantly, the new agents will be 'orchestrator agents,' meaning that they will act as supervisors for groups of 'sub-agents' that each have their own specialties; the supervising agent will route a received task to the appropriate sub-agent, enabling an efficient and automated workflow. Using this technology, IQVIA is hoping to tackle some of the hardest problems in the drug development and pharmaceutical workflows. For example, clinical trials often require a significant amount of work to launch and execute. Agents can help identify targets, develop a knowledge base using existing research databases and even review clinical data to better understand insights and automate the review process. Avinob Roy, vice president and general manager at IQVIA, explains that AI agents will transform the entire 'molecule to market' lifecycle. Overall, the news comes at a time when Nvidia's reach into the AI ecosystem has been incredibly impactful. The company indicated in its latest quarterly report a continuing surge in demand for its GPUs and hardware ecosystem. Though most traditionally a hardware giant, it has also increasingly diversified its work into the cloud and software ecosystems, furthering its moat in the AI space. Undoubtedly, there is stiff competition in the AI race. With regard to hardware alone, technology giants such as Google and Amazon depend heavily on Nvidia for its GPUs; however, the companies are also rapidly developing their own silicon products, such as Google's work with tensor processing units (TPUs) and Amazon's customized silicon products (i.e., Trainium, Graviton and Inferentia). With regard to healthcare and life-sciences more broadly, all of the large technology hyperscalers are investing billions of dollars in these fields. For example, one of the most prominent success stories is Alphabet's Isomorphic Labs and its work with drug development models. Companies like Microsoft are also rolling out new enterprise grade tools and infrastructure capabilities to empower traditional life-science companies. Indeed, the innovation is rapid and unprecedented. Despite the perception of a 'competition' however, there is no need for a clear cut winner. The reality of this progress across the entire spectrum of technology companies is that ultimately, both the healthcare and life-sciences industries stand to gain immense benefits.